McKechnie Duncan 4

What Happened

• McKechnie Duncan, EVP & Chief Commercial Officer of Vertex Pharmaceuticals (VRTX), was credited with two awards totaling 6,800 shares on 2026-01-22: 4,720 shares and 2,080 shares, each reported at $0.00 (award/grant). These are earned performance shares (not open-market purchases or sales). The awards were certified by the company’s compensation committee on 01/22/2026 and will vest on the dates below.

Key Details

• Transaction date: 2026-01-22; Form 4 filed: 2026-01-26 (filed within the standard two-business-day window).
• Reported awards: 4,720 shares @ $0.00 (footnote F1) and 2,080 shares @ $0.00 (footnote F2); total = 6,800 shares.
• Vesting / origin: F1 = PSU granted 02/01/2023; certified 01/22/2026; those shares vest on 02/13/2026. F2 = PSU granted 02/12/2025; certified 01/22/2026; those shares vest in installments beginning 02/24/2026.
• Shares owned after transaction: not disclosed in this filing.
• Filing timeliness: Filed 01/26/2026 for a 01/22/2026 transaction — appears timely (within two business days).
• Nature of transaction: Award of performance-vested shares (code A). Dollar value is reported as $0 because these are earned equity awards; market value will depend on VRTX share price at vesting or sale.

Context

• These are performance-based equity awards, not purchases or sales. They reflect compensation tied to pre-established performance goals; they do not by themselves signal an insider buying or selling stock. Retail investors should note the shares will only convert to owned stock upon vesting and are subject to the award terms.